| pubmed-article:19616429 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:19616429 | lifeskim:mentions | umls-concept:C0034833 | lld:lifeskim |
| pubmed-article:19616429 | lifeskim:mentions | umls-concept:C0226896 | lld:lifeskim |
| pubmed-article:19616429 | lifeskim:mentions | umls-concept:C0205531 | lld:lifeskim |
| pubmed-article:19616429 | lifeskim:mentions | umls-concept:C0442027 | lld:lifeskim |
| pubmed-article:19616429 | lifeskim:mentions | umls-concept:C1527415 | lld:lifeskim |
| pubmed-article:19616429 | lifeskim:mentions | umls-concept:C0243192 | lld:lifeskim |
| pubmed-article:19616429 | lifeskim:mentions | umls-concept:C0205177 | lld:lifeskim |
| pubmed-article:19616429 | lifeskim:mentions | umls-concept:C0728938 | lld:lifeskim |
| pubmed-article:19616429 | lifeskim:mentions | umls-concept:C1880355 | lld:lifeskim |
| pubmed-article:19616429 | pubmed:issue | 16 | lld:pubmed |
| pubmed-article:19616429 | pubmed:dateCreated | 2009-7-29 | lld:pubmed |
| pubmed-article:19616429 | pubmed:abstractText | We have designed and synthesized a novel series of pyrrolidinones as progesterone receptor partial agonists. Compounds from this series had improved AR selectivity, rat pharmacokinetic properties, and in vivo potency compared to the lead compound. In addition, these compounds had improved selectivity against hERG channel inhibition. | lld:pubmed |
| pubmed-article:19616429 | pubmed:language | eng | lld:pubmed |
| pubmed-article:19616429 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19616429 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:19616429 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19616429 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19616429 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19616429 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19616429 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:19616429 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:19616429 | pubmed:issn | 1464-3405 | lld:pubmed |
| pubmed-article:19616429 | pubmed:author | pubmed-author:GrygielkoEuge... | lld:pubmed |
| pubmed-article:19616429 | pubmed:author | pubmed-author:HammondMarlys... | lld:pubmed |
| pubmed-article:19616429 | pubmed:author | pubmed-author:WashburnDavid... | lld:pubmed |
| pubmed-article:19616429 | pubmed:author | pubmed-author:BrayJeffrey... | lld:pubmed |
| pubmed-article:19616429 | pubmed:author | pubmed-author:HoangTram HTH | lld:pubmed |
| pubmed-article:19616429 | pubmed:author | pubmed-author:StewartEugene... | lld:pubmed |
| pubmed-article:19616429 | pubmed:author | pubmed-author:WilliamsShawn... | lld:pubmed |
| pubmed-article:19616429 | pubmed:author | pubmed-author:DuraiswamiCha... | lld:pubmed |
| pubmed-article:19616429 | pubmed:author | pubmed-author:TranThuy BTB | lld:pubmed |
| pubmed-article:19616429 | pubmed:author | pubmed-author:ThompsonScott... | lld:pubmed |
| pubmed-article:19616429 | pubmed:author | pubmed-author:MadaussKevin... | lld:pubmed |
| pubmed-article:19616429 | pubmed:author | pubmed-author:NagillaRakesh... | lld:pubmed |
| pubmed-article:19616429 | pubmed:author | pubmed-author:TriznaWalterW | lld:pubmed |
| pubmed-article:19616429 | pubmed:author | pubmed-author:MannsSharadaS | lld:pubmed |
| pubmed-article:19616429 | pubmed:author | pubmed-author:FrazeeJames... | lld:pubmed |
| pubmed-article:19616429 | pubmed:author | pubmed-author:GlaceLindsay... | lld:pubmed |
| pubmed-article:19616429 | pubmed:author | pubmed-author:JohnsonLatish... | lld:pubmed |
| pubmed-article:19616429 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:19616429 | pubmed:day | 15 | lld:pubmed |
| pubmed-article:19616429 | pubmed:volume | 19 | lld:pubmed |
| pubmed-article:19616429 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:19616429 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:19616429 | pubmed:pagination | 4664-8 | lld:pubmed |
| pubmed-article:19616429 | pubmed:meshHeading | pubmed-meshheading:19616429... | lld:pubmed |
| pubmed-article:19616429 | pubmed:meshHeading | pubmed-meshheading:19616429... | lld:pubmed |
| pubmed-article:19616429 | pubmed:meshHeading | pubmed-meshheading:19616429... | lld:pubmed |
| pubmed-article:19616429 | pubmed:meshHeading | pubmed-meshheading:19616429... | lld:pubmed |
| pubmed-article:19616429 | pubmed:meshHeading | pubmed-meshheading:19616429... | lld:pubmed |
| pubmed-article:19616429 | pubmed:meshHeading | pubmed-meshheading:19616429... | lld:pubmed |
| pubmed-article:19616429 | pubmed:meshHeading | pubmed-meshheading:19616429... | lld:pubmed |
| pubmed-article:19616429 | pubmed:meshHeading | pubmed-meshheading:19616429... | lld:pubmed |
| pubmed-article:19616429 | pubmed:meshHeading | pubmed-meshheading:19616429... | lld:pubmed |
| pubmed-article:19616429 | pubmed:meshHeading | pubmed-meshheading:19616429... | lld:pubmed |
| pubmed-article:19616429 | pubmed:meshHeading | pubmed-meshheading:19616429... | lld:pubmed |
| pubmed-article:19616429 | pubmed:year | 2009 | lld:pubmed |
| pubmed-article:19616429 | pubmed:articleTitle | Discovery of orally active, pyrrolidinone-based progesterone receptor partial agonists. | lld:pubmed |
| pubmed-article:19616429 | pubmed:affiliation | Department of Chemistry, Metabolic Pathways Centre for Excellence in Drug Discovery, GlaxoSmithKline Pharmaceuticals, King of Prussia, PA 19406, USA. dave.g.washburn@gsk.com | lld:pubmed |
| pubmed-article:19616429 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | http://linkedlifedata.com/r... | pubmed-article:19616429 | lld:chembl |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:19616429 | lld:pubmed |
